Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Prophase Labs ( (PRPH) ) has issued an update.
On August 27, 2025, ProPhase Labs, Inc. announced the termination of its Common Stock Purchase Agreement with Keystone Capital Partners, LLC, which was initially established on January 29, 2025. This agreement allowed ProPhase Labs to sell shares of its common stock to Keystone up to approximately $7.7 million. The termination, effective August 28, 2025, was executed at the company’s discretion without any penalties or fees, and there are no other material relationships between the two entities.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
Spark’s Take on PRPH Stock
According to Spark, TipRanks’ AI Analyst, PRPH is a Neutral.
Prophase Labs’ overall stock score is primarily impacted by its financial challenges, including declining revenues and negative profitability. While the earnings call provided some optimism with potential cash recovery and new product developments, these are offset by current financial distress and weak technical indicators. The negative valuation metrics further weigh down the score.
To see Spark’s full report on PRPH stock, click here.
More about Prophase Labs
Average Trading Volume: 6,510,697
Technical Sentiment Signal: Sell
Current Market Cap: $14.26M
Find detailed analytics on PRPH stock on TipRanks’ Stock Analysis page.